Associated tags: Drug discovery, Public, Collection, Research, History, Government, ATCC, Science, Health, Biotechnology, Doctor of Philosophy, Pharmaceutical, Pharmaceutical industry, Genetics, Infectious Diseases, Public health, Senior, Stem Cells, Vaccine, Oncology, Other Science
Locations: VIRGINIA, UNITED STATES, NORTH AMERICA, BARDA, MS, MARYLAND
Biotechnology,
Health,
Oncology,
Clinical Trials,
NCI,
BAAS,
Research,
HHS,
National Cancer Institute,
Cancer,
Doctor of Philosophy,
IDIQ,
NIH,
MBA,
PMP,
National Institutes of Health,
Division,
Bangladesh Technical Education Board,
Collection,
Federal,
Federation This task order, 75N91022D0002.75N91024F00001, under the Division of Cancer Epidemiology and Genetics (DCEG) Field and Biospecimen Support Services’ Multiple Award Indefinite Delivery/Indefinite Quantity (IDIQ), will assist the DCEG’s Biospecimen Activity and Assay Support (BAAS) program by providing biospecimen processing services, as well as molecular and genetic assays, for epidemiologic and clinical cancer research studies.
Key Points:
- This task order, 75N91022D0002.75N91024F00001, under the Division of Cancer Epidemiology and Genetics (DCEG) Field and Biospecimen Support Services’ Multiple Award Indefinite Delivery/Indefinite Quantity (IDIQ), will assist the DCEG’s Biospecimen Activity and Assay Support (BAAS) program by providing biospecimen processing services, as well as molecular and genetic assays, for epidemiologic and clinical cancer research studies.
- “For more than a decade, we have been supporting researchers within the DCEG community by supplying the high-quality biospecimen processing services they need to achieve results and scientific breakthroughs,” said ATCC chairman and CEO Raymond H. Cypess, DVM, PhD.
- “At ATCC, we offer credible high-quality clinical services that support complex research,” said Rebecca Bradford , MBA, MS, PMP, vice president of Government Programs within ATCC Federal Solutions .
- “With this new DCEG contract, we continue to provide innovative solutions to support its Biospecimen Activity and Assay Support program.”
Agriculture,
BioBrick,
Synthetic biology,
Education,
College of Engineering (KNUST),
Climate change,
Health,
Collection,
International,
Research,
ATCC,
Biotechnology,
Creativity,
Doctor of Philosophy WATERTOWN, Mass. and MANASSAS, Va., April 2, 2024 /PRNewswire/ -- Cultivarium, the focused research organization creating open-source tools to expand access to uncharacterized microorganisms, and ATCC, the world's premier biological materials management and standards organization, today announced a groundbreaking collaboration to help iGEM 2024 teams access non-model microbes for biotechnology. The annual iGEM Competition involves multidisciplinary student teams from across the globe that compete for medals and awards by designing, building, and testing genetically engineered systems using standard biological parts called BioBricks. Working in and outside the lab, iGEM teams aim to create sophisticated synthetic biology projects that can positively contribute to their communities and the world.
Key Points:
- Working in and outside the lab, iGEM teams aim to create sophisticated synthetic biology projects that can positively contribute to their communities and the world.
- Cultivarium and ATCC are committing to empowering the creativity of iGEM teams with diverse and innovative microbial resources to expand the horizons of synthetic biology research.
- "By pairing Cultivarium's capabilities and ATCC's enormous and taxonomically diverse collection of microbes we can support iGEM teams to be bold, creative and drive breakthroughs in synthetic biology."
- Together, Cultivarium and ATCC are poised to revolutionize the landscape of synthetic biology by equipping iGEM teams with the tools and resources needed to tackle global challenges and unlock the full potential of non-model microbes.
Retrieved on:
Tuesday, February 27, 2024
Technology,
Health Technology,
Cardiology,
Software,
Biotechnology,
Hardware,
Health,
Pharmaceutical,
Artificial Intelligence,
Nature Biomedical Engineering,
Doctor of Philosophy,
BIRD Foundation,
Intelligence,
DVM,
Drug development,
Arrhythmia,
Al-Quds,
Physiology,
Organoid,
Bionics,
Safety,
Cardiotoxicity,
Hebrew University of Jerusalem,
BIRD,
Research,
Partnership,
Medical device The collaboration will be done under the Israel-U.S. Binational Industrial Research and Development Foundation (BIRD) framework, which awarded both companies a two-year grant.
Key Points:
- The collaboration will be done under the Israel-U.S. Binational Industrial Research and Development Foundation (BIRD) framework, which awarded both companies a two-year grant.
- The BIRD Foundation, established in 1977, bolsters transformative partnerships that stimulate, promote, and support industrial research and development in a wide range of technology sectors.
- Tissue Dynamics partnered with the Hebrew University of Jerusalem to develop the world’s first mature self-paced multi-chambered cardiac organoid model , using ATCC cells, that emulates critical aspects of human physiology.
- Tissue Dynamics’ partnership with ATCC aims to advance this cardiac organoid model for industrial use.
Retrieved on:
Thursday, January 4, 2024
Science,
Research,
Health,
COVID-19,
Infectious Diseases,
Genetics,
Clinical Trials,
Other Health,
Microsoft,
Nextgen,
Infection,
NIAID,
PMP,
Administration,
Vaccine,
CSN,
MBA,
Doctor of Philosophy,
Private sector,
Human services,
Public,
SARS-CoV-2,
Project,
Biological specimen,
Development,
Therapy,
Pharmaceutical industry ATCC will provide cold-chain and lifecycle management of biological specimens from Project NextGen clinical studies.
Key Points:
- ATCC will provide cold-chain and lifecycle management of biological specimens from Project NextGen clinical studies.
- “Protecting the public’s health against multiple coronavirus variants with effective and longer lasting vaccines, as well as more resilient treatments, is critical.
- By working together, we can help find innovative solutions to this challenge.”
Under the Project NextGen initiative, ATCC will provide centralized and standardized services for receipt, processing, storage, protection, retrieval, packaging, shipping, tracking, and distribution of clinical specimens collected from participants across several clinical trials, including Phase IIb efficacy trials.
- This further expands ATCC’s operation of BARDA’s Medical Countermeasures Clinical Studies Network ( CSN ) Biological Specimen and Investigational Product ( BSIP ) storage facility, which also provides centralized services, storage, and distribution of its clinical samples and investigational products across BARDA-supported studies.
Retrieved on:
Thursday, November 30, 2023
Research,
Infectious Diseases,
Clinical Trials,
Stem Cells,
Biotechnology,
AIDS,
General Health,
Pharmaceutical,
Health,
Science,
NIAID,
HIV/AIDS,
Biology,
Vaccine,
DVM,
Infection,
National Institutes of Health,
Human services,
HIV,
NIH,
MBA,
Contract research organization,
Bangladesh Technical Education Board,
Health department,
Public,
Pharmaceutical industry,
ATCC NIAID has made an initial award of over $21.5 million, with further funding expected if all project milestones are met.
Key Points:
- NIAID has made an initial award of over $21.5 million, with further funding expected if all project milestones are met.
- This contract will merge the NIH HIV Reagent Program with the BEI Resources Program under the Biological and Emerging Infections Research Resources Program (BEI-RRP) umbrella.
- ATCC has managed the BEI Resources Program since 2003 and the NIH HIV Reagent Program since 2020.
- At the discretion of NIAID, it will also be a resource for materials produced by other government-supported research projects and service programs.
Retrieved on:
Tuesday, November 28, 2023
Research,
Infectious Diseases,
Clinical Trials,
Stem Cells,
Biotechnology,
Health,
Pharmaceutical,
General Health,
Science,
NIAID,
Disease,
Acquisition,
Vaccine Research Center,
VRC,
NIH Intramural Research Program,
Air tasking order,
Bioterrorism,
Vaccine,
Laboratory,
DVM,
IDIQ,
API,
Infection,
COVID-19,
Biomedical Research,
NIH,
MBA,
Indefinite,
Comprehensive,
CGMP,
Doctor of Philosophy,
Active ingredient,
Bangladesh Technical Education Board,
Public,
IRP,
Pharmaceutical industry,
ATCC The Task Order is part of the Storage Facility Task Area under the Comprehensive and Rapid Response to NIAID Research Programs (CARRRP).
Key Points:
- The Task Order is part of the Storage Facility Task Area under the Comprehensive and Rapid Response to NIAID Research Programs (CARRRP).
- NIAID’s CARRRP provides the capacity and capability for a broad range of services necessary to support and conduct comprehensive and rapid biomedical research.
- Under the CARRRP Task Order, ATCC will manage critical biomaterials for the Vaccine Research Center (VRC), one of the three intramural divisions of NIAID’s Intramural Research Program (IRP).
- “We look forward to working with NIAID and its Intramural Research Program as part of the CARRRP.”
Retrieved on:
Friday, November 10, 2023
Health,
Genetics,
Other Science,
Research,
Science,
Pharmaceutical,
Biotechnology,
Astronaut,
Singular,
Medicine,
ISS,
Agriculture,
DNA,
International Space Station,
ISS National Lab,
DVM,
SpaceX,
University,
Molecular reference standards,
Doctor of Philosophy,
NGS,
ATCC ATCC , the world’s premier biological materials management and standards organization, today announced that ATCC catalog item MSA-2003-ISS was sent to the International Space Station ( ISS National Lab ) on November 9th aboard the SpaceX CRS-29 Cargo Dragon Resupply Craft mission.
Key Points:
- ATCC , the world’s premier biological materials management and standards organization, today announced that ATCC catalog item MSA-2003-ISS was sent to the International Space Station ( ISS National Lab ) on November 9th aboard the SpaceX CRS-29 Cargo Dragon Resupply Craft mission.
- “This is the first time that our products will be used in space to study microbial cells in microgravity,” said ATCC chairman and CEO Raymond H. Cypess , DVM, PhD.
- It is a functioning research laboratory with the tools and facilities needed to translate traditional ground-based experiments into flight-ready payloads.
- MSA-2003-ISS will be used in the uTitan DNA extraction payload studies to demonstrate extraction efficiency in zero gravity.
Retrieved on:
Tuesday, November 7, 2023
Research,
Infectious Diseases,
Stem Cells,
Biotechnology,
Health,
Pharmaceutical,
Other Science,
Science,
Oncology,
National Institute of Allergy and Infectious Diseases,
IND,
DVM,
Indefinite,
NIAID,
Senior,
Private sector,
IDIQ,
NIH,
Infection,
Bangladesh Technical Education Board,
Investigational New Drug,
Pharmaceutical industry,
ATCC ATCC , the world’s premier biological materials management and standards organization, today announced that it has been awarded an Indefinite Delivery/Indefinite Quantity (IDIQ) contract 75N93023D00009 by the National Institute of Allergy and Infectious Diseases ( NIAID ), part of the National Institutes of Health (NIH).
Key Points:
- ATCC , the world’s premier biological materials management and standards organization, today announced that it has been awarded an Indefinite Delivery/Indefinite Quantity (IDIQ) contract 75N93023D00009 by the National Institute of Allergy and Infectious Diseases ( NIAID ), part of the National Institutes of Health (NIH).
- With this contract, ATCC, as a member in the NIAID selected service provider pool, will support NIAID’s Preclinical Services for Biopharmaceutical Product Development in two main areas: the development and validation of analytical assays for product characterization and process development and formulation.
- “This contract builds upon the work we are already doing with NIAID and several of their divisions, as well as our management of NIAID’s BEI Resources,” said Joseph Leonelli, Ph.D., Senior Vice President and General Manager of ATCC Federal Solutions.
- “With our expertise and resources, NIAID is better able to more quickly diagnose infectious disease-causing pathogens and toxins, and then strive to develop therapeutic products to treat them.”
Retrieved on:
Thursday, November 2, 2023
Science,
Stem Cells,
Biotechnology,
Research,
Oncology,
Health,
Infectious Diseases,
Genetics,
Moores Cancer Center,
Biorepository,
DVM,
Faculty of Medical Sciences, University of Buenos Aires,
Head,
Publication,
Doctor of Philosophy,
National Institute of Dental and Craniofacial Research,
Hospital Rivadavia,
HNSCC,
Mouse Models of Human Cancer database,
Medicine,
Breast cancer,
Medical research,
University,
University of California, San Diego,
Collection,
Breast,
Bangladesh Technical Education Board,
Neck,
Management,
Pathology,
ATCC,
MD,
Biology,
Cancer “Alfredo’s scientific expertise in pathology, oncology and histotechnology will be a great resource for our company,” said ATCC Chairman and CEO Raymond H. Cypess , DVM, PhD.
Key Points:
- “Alfredo’s scientific expertise in pathology, oncology and histotechnology will be a great resource for our company,” said ATCC Chairman and CEO Raymond H. Cypess , DVM, PhD.
- Dr. Molinolo earned both his PhD in oncology and MD in medicine from the University of Buenos Aires in Argentina.
- Dr. Molinolo has received several awards and has written numerous publications about breast, oral, and head and neck cancer.
- “Serving on the Board is an opportunity for me to make further contributions to science,” said Dr. Molinolo.
MANASSAS, Va. and ROCKVILLE, Md., Oct. 30, 2023 /PRNewswire/ -- Today, ATCC and U.S. Pharmacopeia (USP), two premier materials management and standards organizations, announced the launch of their first set of joint products to advance the quality control and reduce the risk in the manufacturing of biological therapies and vaccines. This initial set of six products consists of highly characterized and pure genomic DNA (gDNA) from cell lines used in bioproduction that can be used to measure residual host cell DNA in various biotherapeutic products, as required by regulatory authorities. The presence of gDNA is a predominant concern in the development of biological therapies as it can pose a safety risk if it is not removed from the product.
Key Points:
- MANASSAS, Va. and ROCKVILLE, Md., Oct. 30, 2023 /PRNewswire/ -- Today, ATCC and U.S. Pharmacopeia ( USP ), two premier materials management and standards organizations, announced the launch of their first set of joint products to advance the quality control and reduce the risk in the manufacturing of biological therapies and vaccines.
- The presence of gDNA is a predominant concern in the development of biological therapies as it can pose a safety risk if it is not removed from the product.
- By focusing on the detection of gDNA, this first set of ATCC and USP products is significant for the future of biological development as it addresses a common concern when it comes to quality and mitigating risk."
- The first set of products from ATCC and USP allows users to test the drug substance and process intermediates to assess clearance of residual gDNA with analytical reference materials derived from an authenticated cell line.
